Ampiroxicam

Ampiroxicam is an orally active prodrug of non-steroidal anti-inflammatory drug (NSAID). Ampiroxicam inhibits paw swelling in adjuvant-induced arthritis and acute inflammation models, and suppresses phenylbenzoquinone-induced stretching responses in mice. Ampiroxicam is rapidly and completely converted to Piroxicam (HY-B0253) via non-specific esterases and first-pass metabolism. Ampiroxicam induces contact hypersensitivity and photosensitivity reactions through photoproducts generated by UVA. Ampiroxicam can be used in research related to photosensitivity, adjuvant-induced arthritis, rheumatism, osteoarthritis and other inflammatory diseases^[1][2][3][4]. In Vivo:Ampiroxicam (1%; topical occlusive patch; daily for 3 consecutive days; single dose on day 9; single dose on day 21) induces contact hypersensitivity in female Hartley guinea pigs. Sensitized animals show positive responses to UVA-irradiated ampiroxicam and cross-react with thiosalicylates, but do not respond to non-irradiated ampiroxicam or piroxicam^[1].
Ampiroxicam (1-4.1 mg/kg; p.o.; single dose) inhibits the stretching response in fasted CF-1 mice induced by benzoquinone, with an MPE₅₀ of 2.0 mg/kg^[2].
Ampiroxicam (4.3-41 mg/kg; p.o.; single daily dose for 5 days) inhibits carrageenan-induced hind paw edema in fasted Sprague-Dawley rats^[2].